The development of the eIF2B GEF activity enhancers ISRIB and 2BAct [5,6] has shown the therapeutic benefit of the modulation of eIF2B activity in a range of cognitive disorders, as discussed below. Here, EIF2B4 is linked to cognitive disorder.